TY - JOUR
T1 - Seventeen years of experience with ATRA-based therapy for acute promyelocytic leukaemia
T2 - Long-term follow-up of patients treated at S. Martino Hospital, Genoa
AU - Clavio, Marino
AU - Ghiso, Anna
AU - Ghiggi, Chiara
AU - Spriano, Mauro
AU - Colombo, Nicoletta
AU - Grasso, Raffaella
AU - Varaldo, Riccardo
AU - Miglino, Maurizio
AU - Pierri, Ivana
AU - Olcese, Francesco
AU - Aquino, Sara
AU - Biasco, Samantha
AU - Balleari, Enrico
AU - Carella, Angelo Michele
AU - Sessarego, Mario
AU - Gobbi, Marco
PY - 2009
Y1 - 2009
N2 - We conducted a long-term follow-up retrospective study on 91 consecutive newly diagnosed acute promyelocytic leukaemia (APL) patients. Induction and consolidation therapy were well-tolerated by most patients. Of the 79 patients who were initially treated with the all-trans retinoic acid (ATRA)-containing regimens, there were 3 haemorrhagic deaths during the first period of therapy (4%) and one in consolidation which was due to infection. Following consolidation, molecular assessment of response was performed on 67 patients, and 66 were found to have achieved cytogenetic and molecular remission (98%). After a median follow-up of 100 months (12-192), 10 of the 75 patients who achieved complete remission (13%) relapsed. Seventy-eight percent of the patients were expected to be alive at 14 years from diagnosis, i.e., 90 and 48% of patients of intermediate-low risk and high risk at presentation, respectively (p=0.0009). Sixty-nine patients were in molecular remission after firstline and/or salvage therapy (74%). To date, 4 patients out of the 91 have undergone salvage allogeneic transplant (4%).
AB - We conducted a long-term follow-up retrospective study on 91 consecutive newly diagnosed acute promyelocytic leukaemia (APL) patients. Induction and consolidation therapy were well-tolerated by most patients. Of the 79 patients who were initially treated with the all-trans retinoic acid (ATRA)-containing regimens, there were 3 haemorrhagic deaths during the first period of therapy (4%) and one in consolidation which was due to infection. Following consolidation, molecular assessment of response was performed on 67 patients, and 66 were found to have achieved cytogenetic and molecular remission (98%). After a median follow-up of 100 months (12-192), 10 of the 75 patients who achieved complete remission (13%) relapsed. Seventy-eight percent of the patients were expected to be alive at 14 years from diagnosis, i.e., 90 and 48% of patients of intermediate-low risk and high risk at presentation, respectively (p=0.0009). Sixty-nine patients were in molecular remission after firstline and/or salvage therapy (74%). To date, 4 patients out of the 91 have undergone salvage allogeneic transplant (4%).
KW - Acute promyelocytic leukaemia
KW - All-trans retinoic acid
KW - Fluorescent in situ hybridization
KW - PML-RARα
UR - http://www.scopus.com/inward/record.url?scp=67449088927&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67449088927&partnerID=8YFLogxK
U2 - 10.3892/or_00000322
DO - 10.3892/or_00000322
M3 - Article
C2 - 19288007
AN - SCOPUS:67449088927
VL - 21
SP - 1045
EP - 1052
JO - Oncology Reports
JF - Oncology Reports
SN - 1021-335X
IS - 4
ER -